Psychedelic Bulletin
Your weekly update on the psychedelics space. Connect the dots in this fast-paced ecosystem with exclusive insights, analysis, and expert comment.
Psychedelic Bulletin #114 – Lawsuit Alleges Compass Stole Trade Secrets; MindMed CMO Turns Activist Shareholder; California Decrim. Bill Tentatively Clears Hurdle
This week: we take a look at the lawsuit brought against Compass Pathways by Terran Biosciences; Compass says a tweet describing Terran as “slime” was due to a hack; former MindMed CMO turns activist shareholder; and more…
Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley Opine on Psychedelics; COMPASS Rallies
This week: our original analysis reveals psychedelics company spending trends; Morgan Stanley identifies psychedelics as disruptive theme; COMPASS Pathways rallies; and more…
Psychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company Enters Death Spiral Financing
This week: our latest Special Report goes inside the challenge to DEA’s proposed scheduling of 5 tryptamines; we take a look at the latest company to enter a ‘death spiral financing’; and more…
Psychedelic Bulletin #111 – Psychedelics on Netflix; House Adopts 2 Psychedelic Research Amendments; Taking the Magic Out of Magic Mushrooms?
This week: the highly-anticipated Netflix adaptation of Pollan’s How to Change Your Mind hits Netflix; 2 amendments to the NDAA that provide scope for psychedelic research are adopted by the House; Stanford Summer Course explores psychedelic policy perspectives; and more…
Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules Public Hearing on Banning 5 Psychedelics
This week: Pollan’s ‘How to Change Your Mind’ comes to Netflix this week; DEA schedules a rare public hearing on its proposed scheduling of five psychedelics; and more…
Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis of NEJM Psilocybin vs. Escitalopram Trial; Off-Label = Off the Rails?
This week: we have guest commentary from JHU’s Sandeep Nayak, who has led reanalysis of the NEJM psilocybin vs. escitalopram trial; Oregon Psilocybin Training tuition fees are out; we look at how off-label use may play out; and more…